Arca
Skip to content
Tools
Tools

GP: Envelope glycoprotein

Protein in Zaire ebolavirus (strain Mayinga-76) (ZEBOV) (Zaire Ebola virus) that 10 drugs act on.

  • Drugs that act on it: 10
  • Approved: 7
  • In phases 1 to 3: 3
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on GP, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 7
  • Other 3

Approved7

Phase 30

    Phase 23

    • Cosfroviximab
    • Larcaviximab
    • Porgaviximab

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 6 of 10 act as: Envelope glycoprotein inhibitor; the rest name their own mechanism.
      AtoltivimabApproved—AntibodyInhibitor2
      MaftivimabApproved—AntibodyInhibitor2
      OdesivimabApproved—AntibodyInhibitor2
      Adenovirus type 26 encoding ebola virus glycoproteinApproved—Vaccine componentVaccine antigenEnvelope glycoprotein vaccine antigen0
      AnsuvimabApprovedRidgeback BiotherapeuticsAntibodyBinding agentEnvelope glycoprotein binding agent0
      Vaccinia virus, modified encoding ebola virus glycoprotein and nucleoproteinApproved—Vaccine componentVaccine antigenEnvelope glycoprotein vaccine antigen0
      Vesicular stomatitis virus encoding ebola virus glycoproteinApproved—Vaccine componentVaccine antigenEnvelope glycoprotein vaccine antigen0
      CosfroviximabPhase 2—AntibodyInhibitor0
      LarcaviximabPhase 2—AntibodyInhibitor0
      PorgaviximabPhase 2—AntibodyInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
      EBOla Post-Exposure ProphylaxisAtoltivimab, Maftivimab, OdesivimabPhase 3Not yet recruitingANRS, Emerging Infectious DiseasesFeb 24, 2025
      Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy VolunteersAtoltivimab, Maftivimab, OdesivimabPhase 2Not yet recruitingANRS, Emerging Infectious DiseasesJan 21, 2022

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4105829, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.